You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
凱普生物(300639.SZ)一季度淨利潤預增583.91%-786.55%
格隆匯 04-01 20:14

格隆匯 4 月 1日丨凱普生物(300639.SZ)公佈,預計2021年第一季度歸屬於上市公司股東的淨利潤1.35億元-1.75億元,同比增長583.91%-786.55%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.305億元-1.705億元,同比增長641.39%-868.63%。業績變動原因如下:

1上年同期,因國內疫情原因,公司HPV、地貧、耳聾基因、STD檢測等產品銷售受醫院門診量下降影響較大,報吿期內相關產品銷售已恢復常態。報吿期內,公司香港及國內醫學檢驗實驗室積極參與疫情防控,業務取得較快增長。報吿期內,因核酸檢測需求增加對配套儀器、取樣耗材、核酸提取試劑等帶來銷售拉動,新冠相關產品出口貢獻一定業務增量。以上重點因素對報吿期內公司業務收入帶來積極影響。

2、報吿期內,預計非經常性損益對公司淨利潤的影響金額約為450萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account